Updated:
Acadia Pharmaceuticals Inc.
Acadia advances care for underserved neurological disorders and rare diseases. It has operated in healthcare since its founding to address the needs of...
Acadia Pharmaceuticals Inc.
Acadia advances care for underserved neurological disorders and rare diseases. It has operated in healthcare since its founding to address the needs of patients requiring the most attention.
General information
Firm type
other
Location
Region
Europe
Country
United States
City
San Diego
Corporate office
12830 El Camino Real, Suite 400, San Diego, CA 92130, United States
Additional offices
Princeton, New Jersey, United States · Oakville, Ontario, Canada · Basel, Switzerland · Zug, Switzerland · Amsterdam, Netherlands
Sector focus
Frequently asked questions
Who runs investment decisions at Acadia Pharmaceuticals?
Acadia Pharmaceuticals is a publicly traded biopharmaceutical company, not a family office or investment firm. Investment and capital allocation decisions are made by its executive leadership and board of directors, as typical for a corporation. The firm's leadership includes a CEO and a management team focused on R&D and commercialization.
How does Acadia source its drug development pipeline?
Acadia develops therapies through internal research and development as well as external partnerships and collaborations. The firm states it actively seeks partnerships that drive therapeutic advancements for patients. Its published pipeline focuses on neurological disorders and rare diseases, with a history of advancing candidates from early research to FDA approval.
Is Acadia a family office or asset manager?
No. Acadia Pharmaceuticals is a publicly traded biopharmaceutical company (NASDAQ: ACAD), not a family office, asset manager, or investment vehicle. It operates as a drug developer and commercializer for neurological and rare disease indications.
What investment stages does Acadia typically target?
Acadia is not an investment firm; it does not target investment stages. As a pharmaceutical company, it advances drug candidates from preclinical research through clinical trials and regulatory approval.
Which sectors does Acadia explicitly avoid?
Acadia does not publicly disclose avoided sectors. Its stated focus is on neurological disorders and rare diseases with limited treatment options, including Parkinson's disease psychosis, Rett syndrome, and Alzheimer's disease psychosis.
Does Acadia maintain philanthropic structures?
Acadia has a corporate responsibility program anchored in ethics and sustainability, but does not publicly disclose a separate philanthropic foundation or charitable vehicle. The company's programs focus on patient and community support, including patient stories and partnerships detailed on its website.
Where does the underlying wealth come from for Acadia?
Acadia Pharmaceuticals is a publicly traded company, generating revenue through sales of its approved drugs (NUPLAZID and DAYBUE) and financing through equity/debt markets. Wealth is generated from commercial operations, not from any individual or family fortune.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: